Fluconazole susceptibility of invasive Candida sp isolates as determined by three methods. Bogota - Colombia;Evaluación mediante tres técnicas de susceptibilidad a fluconazol en especies de Candida aisladas en pacientes con infecciones invasoras. Bogotá - Colombia

Revista Chilena de Infectologia

Volumn 26, Issue 2, 2009, Pages 135-143

  Torres D, Nidia A ^a   Álvarez M, Carlos A ^a   Rondón S, Martín A ^b  

^a HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

Antifungal agents; Candida; Fluconazole; Fungal drugs sensitivity tests

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ARTICLE; CANDIDA; CLASSIFICATION; COLOMBIA; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

ANTIFUNGAL AGENTS; CANDIDA; COLOMBIA; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 67651165624     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Neely M, Ghannoum M. The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 897-914.
2. Carrillo A, Abarca L, Quindós G. Métodos colorimétricos para la determinación de la sensibilidad in vitro a los antifúngicos. Rev Iberoam Micol 2001; 18: 150-5.
3. Cuenca-Estrella M, Rodríguez-Tudela J. ¿Pueden basarse las indicaciones de los antifúngicos en los estudios de sensibilidad?. Rev Iberoam Micol 2002; 19: 133-8.
4. Johnson Elizabeth M. Issues in antifungal susceptibility testing. J Antimicrob Chemother 2008; 61 (Suppl). 1, il3-il8.
5. Espinel-Ingroff A. Antifungal susceptibility testing. Clin Microbiol Newsletter 1996; 18: 161-7.
6. Barry AL, Pfaller MA, Rennie RP, Fuchs PC, Brown SD. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother 2002; 46: 1781-4.
7. Forrest G. Role of antifungal susceptibility testing in patient management. Curr Opin Infect Dis 2006; 6: 538-43.
8. Klevay M, Ebinger A, Diekema D, Messer S, Hollis R, Pfaller M. Disk diffusion testing using Candida sp. colonies taken directly from CHROMagar medium may decrease time required to obtain results. J Clin Microbiol 2005; 43: 3497-9.
9. Tan G, Peterson E. CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures. J Clin Microbiol 2005; 43: 1727-31.
10. NCCLS (National Committee for Clinical Laboratory Standards). 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard-Second Edition. NCCLS document M27-A2 (ISBN 1-56238-469-4). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
11. NCCLS. 2003. Method for antifungal disks diffusion susceptibility testing of yeasts; proposed guideline. NCCLS Document M44-P (ISBN 1-56238-488-0). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
12. Chryssantou E. Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of E-test and the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A reference method. J Clin Microbiol 2001; 39: 4181-3.
13. Gudlaugsson O, Gillespie S, Lee K, Vande-Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
14. Berrouane Y, Herwaldt L, Pfaller M. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999; 37: 531-7.
15. Bustamante C. Treatment of Candida infection: a view from the trenches! Curr Opin Infect Dis 2005; 18: 490-5.
16. Sabatelli F, Patel R, Mann P, Mendrick C, Norris C, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
17. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-4.
18. Cortés J, Leal A, Alvarez C. Frecuencia de aislamientos micóticos en hospitales de tercero y cuarto nivel en Bogotá, 2001-2002. Infectio 2003; 7: 110.
19. Samra Z, Yardeni M, Peled N, Bishara J. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. Eur J Clin Microbiol Infect Dis 2005; 24: 592-5.
20. St-Germain G, Laverdière M, Pelletier A, Bourgault M, Libman M, Lemieux C, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2000; 3: 949-53.
21. Testore G, Dori L, Buonomini A, Schito G, Soro O, Fortina G, et al. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines. Diagn Microbiol Infect Dis 2004; 50: 187-92.
22. Pfaller M, Jones R, Doern G, Sader H, Hollis R, Messer S. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program. J Clin Microbiol 1998; 36: 1886-9.
23. Pfaller M, Jones R, Doern G, Sader H, Messer S, Houston A. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-51.
24. Pfaller M, Diekema D, Gibbs D, Newell V, Meis J, Gould I, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5- year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735-45.
25. Rivas J, Cortés J, Cuervo S, Vanegas E, Bermúdez D. Resistencia al fluconazol en aislamientos clínicos de Candida en un centro de referencia de pacientes con cáncer. Libro de Resúmenes V Congreso Panamericano de Control de Infecciones y Epidemiología Hospitalaria y I Congreso Peruano de Control de Infecciones Hospitalarias. Rev Peruana Enf Infec Trop 2004. 7-10 oct. Lima-Perú.
26. De Bedout C, Ayabaca J, Vega R, Méndez M, Santiago A, Pabón M. Evaluación de la susceptibilidad de especies de Candida al fluconazol por el método de difusión de disco. Biomédica 2003; 23: 31-7.
27. Villar L, Díaz F, Céspedes J, Torres A, De Bedout C. Patrones de sensibilidad y resistencia de asilamiento de Candida en pacientes críticos de la ciudad de Bucaramanga. Infectio 2002; 6: E-12.
28. Gutiérrez C, De Bedout C, Tobón A, Cano L, Arango M, Tabares A, et al. Sensibilidad al fluconazol y voriconazol de aislamientos de Candida spp, obtenidos de mucosa oral de pacientes con SIDA. Infectio 2007; 11: 183-9.
29. Tortorano A, Rigoni A, Biraghi E, Prigitano A, Viviani M, FIMUA-ECMM candidaemia study group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-82.
30. Silva V, Díaz M, Febrè N y red de diagnóstico en micología médica. Vigilancia de la resistencia de levaduras a antifúngicos. Rev Chil Infec 2002; 19: S149-56.
31. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of E-test and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-40.
32. Gil J, Rubio C, Benito R. Criterios de sensibilidad a los azoles. Rev Esp Quimioterap 2004; 17: 83-90
33. Capoor M, Nair D, Deb M, Verma P, Srisvastava L, Aggarwal P. Emergence of non-Candida species and antifungal resistance in a tertiary care hospital. Jpn J Infect Dis 2005; 58: 344-8.
34. Finquelievich J, Iovannitti C, Mujica M, Rellos S, De Elias Costa M, Jewtuchowicz V, et al. Susceptibility of Candida species to fluconazole assayed by a disk diffusion method with automated reading versus a microdilution method. Rev Argent Microbiol 2003; 35: 214-8.
35. Pfaller M, Liang Yu W. Antifungal susceptibility testing. Infect Dis Clin North Am 2001; 15: 1227-61.
36. Pfaller M, Diekema D, Rinaldi M, Barnes R, Hu B, Veselov A, et al. and the Global Antifungical Surveillance Group. Results from ARTEMIS DISK Global Antifungal Surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazol and voriconazol by standardized disk diffusion testing. J Clin Micorbiol 2005; 43: 5848-59.